Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :30096128
Publication Date : //

Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.


Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Development of chemoresistance and peritoneal dissemination are the major reasons for low survival rate in the patients. The bromodomain and extraterminal domain (BET) proteins are known as epigenetic 'readers,' and their inhibitors are novel epigenetic strategies for cancer treatment. Accumulating body of evidence indicates that epigenetic modifications have critical roles in development of EOC, and overexpression of the BET family is a key step in the induction of important oncogenes. Here, we examined the mechanistic activity of I-BET151, a pan-inhibitor of the BET family, in therapy-resistant EOC cells. Our findings showed that I-BET151 diminished cell growth, clonogenic potential, and induced apoptosis. I-BET151 inhibited cell proliferation through down-modulation of FOXM1 and its targets aurora kinase B and cyclin B1. I-BET151 attenuated migration and invasion of the EOC cells by down-regulation of epithelial-mesenchymal transition markers fibronectin, ZEB2, and N-cadherin. I-BET151 synergistically enhanced cisplatin chemosensitivity by down-regulation of survivin and Bcl-2. Our data provide insights into the mechanistic activity of I-BET151 and suggest that BET inhibition has potential as a therapeutic strategy in therapy-resistant EOC. Further in vivo investigations on the therapeutic potential of I-BET151 in EOC are warranted.

Authors : Momeny Majid , Eyvani Haniyeh , Barghi Farinaz , Ghaffari Seyed H , Javadikooshesh Sepehr , Hassanvand Jamadi Robab , Esmaeili Fatemeh , Alishahi Zivar , Zaghal Azam , Bashash Davood , Samani Fazel S , Ghaffari Parisa , Dehpour Ahmad R , Tavangar Seyyed M , Alimoghaddam Kamran , Ghavamzadeh Ardeshir ,

Related products :

Catalog number Product name Quantity
30-121 C21orf33 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggests that growth inhibition induced in these cells by all-trans retinoic acid occurs via 0.1 mg
5-81028 Human ovarian smooth muscle cells, female, 69, ovarian cancer vial
5-81026 Human ovarian epithelial cells (tumor), female, 69, ovarian cancer vial
27-681 NOTCH4 is a member of the Notch family. Members of this Type 1 transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth f 0.05 mg
20-272-192386 Ovarian Carcinoma - associated Antigen - Mouse monoclonal [OV632] to Ovarian Carcinoma - associated Antigen Monoclonal 1 ml
EIAAB28606 Homo sapiens,Human,OCIA,OCIA domain-containing protein 1,OCIAD1,Ovarian carcinoma immunoreactive antigen
EIAAB28610 Homo sapiens,Human,OCIA domain-containing protein 2,OCIAD2,Ovarian carcinoma immunoreactive antigen-like protein
E0154h ELISA CA125,CA-125,Homo sapiens,Human,MUC16,MUC-16,Mucin-16,Ovarian cancer-related tumor marker CA125,Ovarian carcinoma antigen CA125 96T
U0154h CLIA CA125,CA-125,Homo sapiens,Human,MUC16,MUC-16,Mucin-16,Ovarian cancer-related tumor marker CA125,Ovarian carcinoma antigen CA125 96T
E0154h ELISA kit CA125,CA-125,Homo sapiens,Human,MUC16,MUC-16,Mucin-16,Ovarian cancer-related tumor marker CA125,Ovarian carcinoma antigen CA125 96T
GTX24697 Breast tumor (human) ductal carcinoma (invasive) tissue slides 5 slide
GWB-SLI117 Breast tumor (human): ductal carcinoma (invasive) tissue slides
GTX24697 Breast tumor (human) ductal carcinoma (invasive) tissue slides 5 slide
orb60252 Idarubicin HCl Idarubicin is the anthracycline antibiotic and target DNA topoisomerase II (topo II). MCF-7 cells were sensitive to idarubicin, with an IC 50 value for growth inhibition of 0.01 1 mg
'GTX24697 Breast tumor (human) ductal carcinoma (invasive) tissue slides tissues 5 slide
T2235086-2 Paraffin Tissue Section - Human Breast Tumor: Invasive ductal carcinoma 5 slides
BRF404 Breast invasive ductal carcinoma forzen tissue array, 20 cases_40 cores
1108 Her-2 IHC Bio-marker control TMA, for CAP proficiency test survey, with breast invasive ductal carcinoma, 10 cases_10 cores
BR1504 Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores
BR1504 Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 75 cases_150 cores
BRC491 Human breast invasive ductal carcinoma (IDC) tissue array, non_overlapping with BRC711, 49 cases_49 cores
BC08118 Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases_100 cores
BC08118 Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 100 cases_100 cores
HEC14 Human Ovarian Microvascular Endothelial Cells, 500,000+ Cells in T25 Flask.
BRF404 Breast invasive ductal carcinoma forzen tissue array, 20 cases_40 cores; ihc Anti-Actin confirmed


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur